Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

11.64 +0.12 (+1.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

3 Russell 2000 Stocks with Warning Signs

November 13, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

Amneal Receives U.S. FDA Approval for Iohexol Injection

November 13, 2025

First-to-market complex injectable with expected launch in Q1 2026

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Stocks Under $50 We Steer Clear Of

November 11, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

3 Value Stocks We Find Risky

November 09, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Amneal (AMRX) Stock Is Up Today

October 31, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations...

Via StockStory

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗

October 30, 2025

Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars

October 30, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s...

Via StockStory

Amneal Reports Third Quarter 2025 Financial Results

October 30, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

October 29, 2025

Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Earnings: What To Look For From AMRX

October 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Thursday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

October 27, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Cash-Producing Stocks with Questionable Fundamentals

October 27, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 of Wall Street’s Favorite Stocks We Find Risky

October 14, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down

October 09, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

October 06, 2025

From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma

Via Business Wire

3 Lesser-Known Healthcare Names With Major Upside in Store ↗

October 02, 2025

These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.

Via MarketBeat

Amneal to Report Third Quarter 2025 Results on October 30, 2025

September 30, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

September 26, 2025

Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops ↗

September 23, 2025

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.

Via Stocktwits

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

September 23, 2025

Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Low-Volatility Stocks We Find Risky

September 15, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Topics Economy Government World Trade

Why Amneal (AMRX) Stock Is Up Today

September 11, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 4.7% in the afternoon session after the company announced it received U.S. Food and Drug Administration (FDA) approval for...

Via StockStory

Topics Artificial Intelligence Economy

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

September 11, 2025

Expands Amneal’s Affordable Medicines portfolio and broadens patient access

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

September 04, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Hyped Up Stocks with Open Questions

September 04, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Via StockStory

1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down

August 20, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Topics Bonds

Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today